INS and Insulin resistance: It is widely thought that the diminution of first-phase insulin secretion is the earliest detectable defect of pancreatic β-cell function in individuals at high risk for T2DM; this defect largely represents β-cell exhaustion after years of compensation for antecedent insulin resistance.